Industry Self-Regulation Group Sends Questions About PLx Pharma’s Vazalore Claims To FTC
Over past year, PLx's Vazalore ad claimswere reviewed National Advertising Division before and after launch. As PLx appeals NAD’s post-launch review findings, NAD attorneys send questions about pre-launch claims to FTC.
You may also be interested in...
BBB National Programs’ appeals panel agrees with National Advertising Division that PLx should modify TV ad to clearly and conspicuously disclose that “clinically shown to cause fewer ulcers than plain aspirin” refers to Vazalore 325 mg and not 81-mg dose.
PLx disagrees with National Advertising Division’s recommendations following review on Bayer’s challenge of TV commercial and will appeal findings to National Advertising Review Board. NAD attorneys thank PLx’s “ voluntary participation” in SWIFT review but PLx makes clear it didn’t agree to a SWIFT process.
Senate recognizes “dietary supplements have become a routine part of the lives of millions of individuals in the United States” and “the contributions of the natural product industry to the workforce and economy,” says ‘‘Natural Product Industry Week’’ resolution proposed by Sens. Mike Lee and Kyrsten Sinema.